


STN - Registry /CAPLUS

10/506,741

05/10/2006

L1 HAS NO ANSWERS
L1 STR



G1 C, S
G2 H, Me
G3 C, N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 12:58:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 557 TO ITERATE

100.0% PROCESSED 557 ITERATIONS
SEARCH TIME: 00.00.01

✓ 83 ANSWERS

L2 83 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
167.38	167.59

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:58:57 ON 10 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2006 VOL 144 ISS 20
FILE LAST UPDATED: 9 May 2006 (20060509/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 4 L2

=> d ibib ~~abs~~ hitstr 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2005:216670 CAPLUS

DOCUMENT NUMBER:

142:298003

TITLE:

Preparation of thieno[3,2-b]pyrrole amide derivatives as glycogen phosphorylase inhibitors

INVENTOR(S):

Birch, Alan Martin; Simpson, Iain; Stocker, Andrew; Whittamore, Paul Robert Owen

PATENT ASSIGNEE(S):

Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE:

PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020987	A1	20050310	WO 2004-GB3648	20040827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:		GB 2003-20422		A 20030830

OTHER SOURCE(S):

MARPAT 142:298003


GI



AB Title compds. represented by the formula I (wherein B = (un)substituted pyrrolyl-2-carbonyl or indolyl-2-carbonyl; R1 = independently halo, nitro,


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 847684-49-5 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 847684-50-8 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

carbamoyl, alkanoyloxy, etc., R2 = H, (hydroxy)alkyl, alkylcarbamoyl, etc.; A = pyridyl ring; n = 0 or 1; and pharmaceutically acceptable salts or prodrugs thereof were prep. as glycogen phosphorylase inhibitors. For example, II was given in a multi-step synthesis starting from 4,5-dichlorothiophene-2-carboxaldehyde.

II showed thermodyn. soly. (16.2 μM) and plasma-protein binding activity with 0.06 μM. Thus, I and their pharmaceutical compns. are useful as glycogen phosphorylase inhibitors for the treatment of type 2 diabetes, insulin resistance, syndrome X, hyperinsulinemia, hyperglucagonemia, cardiac ischemia or obesity in a warm-blooded animal, such as man (no data).

IT 847684-47-3P 847684-48-4P 847684-49-5P

847684-50-8P 847684-51-9P 847684-52-0P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)

RN 847684-47-3 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 847684-48-4 CAPLUS

CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-51-9 CAPLUS


CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3S)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 847684-52-0 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,8-naphthyridin-3-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 847684-45-1P 847684-46-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)


RN 847684-45-1 CAPLUS

CN 1,5-Naphthyridine-1(2H)-acetic acid, 3-[(2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-46-2 CAPLUS
 CN 1,5-Naphthyridine-1(2H)-acetic acid, 3-[[2,3-dichloro-4H-thieno[3,2-b]pyrrol-5-yl]carbonylamino]-3,4-dihydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 600157-44-6P 600157-52-6P 600157-53-7P
 847684-40-6P 847684-41-7P 847684-42-8P
 847684-43-9P 847684-44-0P 847684-53-1P
 847684-54-2P 847684-55-3P 847684-56-4P
 847684-57-5P 847684-58-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)
 RN 600157-44-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847684-41-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-(3-hydroxypropyl)-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 847684-42-8 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-(2-hydroxyethyl)-2-oxo-1,6-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 847684-43-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-52-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 600157-53-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 847684-40-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(3-hydroxypropyl)-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 847684-44-0 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-1-(2-hydroxyethyl)-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 847684-53-1 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 847684-54-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 847684-55-3 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)


L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 847684-56-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847684-57-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)




L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 847684-74-6P 847684-75-7P 847684-76-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)

RN 847684-74-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847684-75-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)



L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-58-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,6-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 847684-72-4P 847684-73-5P

RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of naphthyridinyl thieno[3,2-b]pyrrole-5-carboxamides as glycogen phosphorylase inhibitors)

RN 847684-72-4 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847684-73-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(3R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-ylmethyl]-1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847684-76-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylthio)ethyl]-2-oxo-1,5-naphthyridin-3-yl]- (9CI) (CA INDEX NAME)







REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:58248 CAPLUS
 DOCUMENT NUMBER: 141:140474
 TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
 INVENTOR(S): Sher, Philip M.; Ellsworth, Bruce A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142938	A1	20040722	US 2003-712823	20031113
PRIORITY APPLN. INFO.:			US 2002-426465P	P 20021114

OTHER SOURCE(S): MARPAT 141:140474
 GI




AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds., G(-O2CR')m(-OH)n(-O2C(CH2)pCH3)q [G = branched or straight C3-5-carbon chain and (-O2CR'), (-OH) and (-O2C(CH2)pCH3) are attached to any available carbon atom along G; m = 1 - 4; n = 0 - 3; p =

0 - 16; q = 0 - 3; where m + n + q = 3 or 4; and -O2CR' is a fragment of a compound I wherein W = W1, W2, W3; X = O, S, SO2, CHR5, , CHR5O, CHR5S, CHR5SO2, CHR5CO, CH2CHR5; Y = bond, CHR6; Z = aryl, heteroaryl; R1 = H, alkyl, alkenyl; R2 = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R3, R4 = H, halo, CF3, CN, alkyl, alkoxy; R5, R6 = H, alkyl, aryl, alkenyl, CN, CN4R9A (tetrazole), CO2R9A, CONR9AR9B, CONR9AOR9B; A = CH, N;

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-B





L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 B = O, S; wherein R1, R2, R5, R6, R7, R8 = alkyl, aryl, alkenyl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy and each may be substituted with 1 - 3 hydrogen bonding groups). Thus, 3-[(5-chloroindolecarbonyl)amino]-3,4-dihydrocarbostyryl I (R1 = R2 = H, W = 5-chloroindole, X = CH2, YZ = benzo) was prepd. from 3-amino-3,4-dihydrocarbostyryl via acylation with 5-chloroindolecarboxylic acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical compns. and methods for treating diabetes and related diseases employing compds. above, either alone or in combination with another therapeutic agent.

IT 724783-28-2P
 RN 724783-28-2 CAPLUS
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)

CN 4-Quinoloneacetic acid, 3-[[[(2-bromo-4H-thieno[3,2-b]pyrrol-5-yl)carbonyl]amino]-1,2,3,4-tetrahydro-2-oxo-, 1,2,3-propanetriyl ester, (3R,3'R,3''R,4S,4'S,4''S)- (SCI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




= 0-2; R1 = halo, NO₂, CN, OH, CO₂H, etc.; R2 = H, OH, CO₂H; R3 = H, OH, aryl, heterocyclyl, etc.] which possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity such as diabetes

IT	compound 1 was claimed.	
	600157-07-1P	600157-08-2P
	600157-18-4P	600157-23-1P
	600157-27-5P	600157-28-6P
	600157-30-8P	600157-41-3P
	600157-47-9P	600157-49-1P
		600653-76-7P
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); TSP (Therapeutic use); BIO (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of thienopyrrolecarboxamides as inhibitors of glycogen phosphorylase)	
RN	600157-07-1	CAPLUS
NAME	1[(2H)-Quinololinecarboxylic acid, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX)	




RN 600157-08-2 CAPLUS
CN 1(2H)-Quinolineacetic acid, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 600157-16-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[[[4S]-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 600157-18-4 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[[{(4R)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-23-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-[2-oxo-2-[(3aR,6aS)-tetrahydro-2,2-dimethyl-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethyl]-3-quinolinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 600157-26-4 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(2,2-dimethyl-1,3-dioxan-5-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-27-5 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
2-chloro-N-[1,2,3,4-tetrahydro-1-[3-
hydroxy-2-(hydroxymethyl)propyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX
NAME)




```

RN      600157-28-6  CAPLUS
CN      4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(2,2-dimethyl-
(CA     1,3-dioxan-5-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI)
        INDEX NAME)


```




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 600157-32-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1-(cyanomethyl)-1,2,3,4-
 tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



RN 600157-38-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-
 (methylthio)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-41-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[2,3-dichloro-6H-thieno[3,2-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX
 NAME)




RN 600157-42-4 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[[[2,3-dichloro-6H-thieno[3,2-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 600157-09-3P 600157-10-6P 600157-11-7P
 600157-12-8P 600157-13-9P 600157-14-0P
 600157-15-1P 600157-17-3P 600157-19-5P
 600157-20-8P 600157-21-9P 600157-22-0P
 600157-24-2P 600157-25-3P 600157-29-7P
 600157-30-0P 600157-31-1P 600157-33-3P
 600157-34-4P 600157-35-5P 600157-36-6P
 600157-37-7P 600157-39-9P 600157-40-2P
 600157-43-5P 600157-44-6P 600157-45-7P
 600157-46-8P 600157-48-0P 600157-50-4P
 600157-52-6P 600157-53-7P 600157-54-8P
 600157-55-9P 600157-73-1P 600157-74-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of thienopyrrolecarboxamides as inhibitors of glycogen
 phosphorylase)

RN 600157-09-3 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-10-6 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-N,N-dimethyl-2-oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-47-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[1,2,3,4-tetrahydro-1-(3-
 hydroxypropyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-49-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-
 oxo-1-(2-oxobutyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600653-76-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[1-[(2Z)-2-amino-2-
 (hydroxyimino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-2-chloro-
 (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-11-7 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-12-8 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-N-hydroxy-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-13-9 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[[2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl]carbonyl]amino]-3,4-dihydro-N-(2-hydroxyethyl)-2-oxo- (9CI) (CA INDEX
 NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-14-0 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[(1,2,3,4-tetrahydro-1-(2-
 hydroxyethyl)-2-oxo-3-quinolinyl)]- (9CI) (CA INDEX NAME)




RN 600157-15-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[(1,2,3,4-dihydroxypropyl)-
 1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)]- (9CI) (CA INDEX NAME)




RN 600157-17-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3R)-1-[(2S)-2,3-
 dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-21-9 CAPLUS
 CN 1(2H)-Quinoloneacetamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonylamino]-3,4-dihydro-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-oxo-
 (9CI) (CA INDEX NAME)




RN 600157-22-0 CAPLUS
 CN 1(2H)-Quinoloneacetamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-
 yl)carbonylamino]-3,4-dihydro-N-[2-methoxyethyl]-2-oxo- (9CI) (CA INDEX
 NAME)




RN 600157-24-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(2-[(3R,4S)-3,4-

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-19-5 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(3R)-1-[(2R)-2,3-
 dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.




RN 600157-20-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide,
 2-chloro-N-[(1,2,3,4-tetrahydro-1-[2-
 (4-hydroxy-1-piperidinyl)-2-oxoethyl]-2-oxo-3-quinolinyl)]- (9CI) (CA
 INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dihydroxy-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-2-oxo-3-
 quinolinyl)]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 600157-25-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-
 1-(dimethylamino)ethyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)]- (9CI) (CA
 INDEX NAME)




RN 600157-29-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide,
 2,3-dichloro-N-[(1,2,3,4-tetrahydro-
 1-[3-hydroxy-2-(hydroxymethyl)propyl]-2-oxo-3-quinolinyl)]- (9CI) (CA
 INDEX NAME)




RN 600157-30-0 CAPLUS


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1(2H)-Quinolineacetamide, 3-[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino-N-(2,3,4-dihydroxypropyl)-3,4-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-31-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-(2-methoxyethyl)-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-33-3 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-37-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, N-[1-[(5-amino-1,3,4-oxadiazol-2-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 600157-39-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylsulfinyl)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-40-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-1-[2-(methylsulfonyl)ethyl]-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 600157-34-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1,2,3,4-tetrahydro-2-oxo-1-(1H-tetrazol-5-ylmethyl)-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-35-5 CAPLUS
 CN 1(2H)-Quinolineacetamide, 3-[[2-chloro-6H-thieno[2,3-b]pyrrol-5-yl]carbonyl]amino-N-(methylsulfonyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 600157-36-6 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)methyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-43-5 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)




RN 600157-44-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[1-[(2R)-2,3-dihydroxypropyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 600157-45-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[(3-(dimethylamino)-2-hydroxypropyl)-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-46-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1-[(2-oxo-1,3-dioxan-5-yl)methyl]-3-quinolinyl)- (9CI) (CA INDEX NAME)]




RN 600157-48-0 CAPLUS
 CN 1(2H)-Quinolinepropanamide, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonylamino]-3,4-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)]




RN 600157-50-4 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1-[(2-oxo-1,3-dioxan-5-yl)methyl]-3-quinolinyl)- (9CI) (CA INDEX NAME)]

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-73-1 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1-[(2-oxo-1,3-dioxan-5-yl)methyl]-3-quinolinyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 600157-74-2 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1-[(2-oxo-1,3-dioxan-5-yl)methyl]-3-quinolinyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




IT 600157-56-0P 600157-59-3P 600157-61-7P
 600157-63-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of thienopyrrolecarboxamides as inhibitors of glycogen phosphorylase)
 RN 600157-56-0 CAPLUS


L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 600157-52-6 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,5-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)]



RN 600157-53-7 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-2-oxo-1,7-naphthyridin-3-yl)- (9CI) (CA INDEX NAME)]




RN 600157-54-8 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(6-fluoro-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)]




RN 600157-55-9 CAPLUS
 CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[(1,2,3,4-tetrahydro-6-methoxy-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)]

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 600157-58-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonylamino]-3,4-dihydro-2-oxo-, hydrazide (9CI) (CA INDEX NAME)]




RN 600157-59-3 CAPLUS
 CN 1(2H)-Quinolineacetic acid, 3-[(2-chloro-6H-thieno[2,3-b]pyrrol-5-yl)carbonylamino]-3,4-dihydro-2-oxo-, hydrazide (9CI) (CA INDEX NAME)]




RN 600157-61-7 CAPLUS
 CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-[(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 600157-63-9 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-[1-[[[1,1-dimethylethyl]dimethylsilyl]oxy]propyl]-1,2,3,4-tetrahydro-2-oxo-3-quinolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:185126 CAPLUS
DOCUMENT NUMBER: 136:247485
TITLE: Preparation of bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
INVENTOR(S): Bartlett, Julie B.; Freeman, Sue; Kenny, Peter; Morley, Andrew; Whittamore, Paul
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020530	A1	20020314	WO 2001-SE1880	20010831
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2417594	AA	20020314	CA 2001-2417594	20010831
AU 2001082833	A5	20020322	AU 2001-82833	20010831
EP 1317459	A1	20030611	EP 2001-961577	20010831
EP 1317459	B1	20040407		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001013606	A	20030624	BR 2001-13606	20010831
JP 2004508376	T2	20040318	JP 2002-525151	20010831
AT 263772	E	20040415	AT 2001-961577	20010831
NZ 524011	A	20040827	NZ 2001-524011	20010831
PT 1317459	T	20040831	PT 2001-961577	20010831
ES 2217183	T3	20041101	ES 2001-1961577	20010831
EE 200300083	A	20041215	EE 2003-83	20010831
ZA 2003001013	A	20040505	ZA 2003-1013	20030205
US 2003232875	A1	20031218	US 2003-344506	20030210
NO 200301024	A	20030305	NO 2003-1024	20030305
BG 107624	A	20040130	BG 2003-107624	20030310
HK 1055299	A1	20041021	HK 2003-107519	20031016
PRIORITY APPL. INFO.:			GB 2000-21831	A 20000906
			WO 2001-SE1880	W 20010831

OTHER SOURCE(S): MARPAT 136:247485
GI


L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [R1 = H, halo, NO2, CN, OH, (un)substituted alkyl, alkenyl, etc.; R2 = H, halo, NO2, CH2F, CHF2, CF3, amino, alkyl, alkenyl, alkoxy, etc.; R3 = H, alkyl; -X-Y-Z- is selected from -S-CR4=CR5-, -CR4=CR5-S-, -O-CR4=CR5-, -CR4=CR5-O-, -N=CR4-S-, -S-CR4=N-, -NR3-CR4=CR5- and -CR4=CR5-NR3- wherein R4 and R5 = independently H, halo, CN, alkyl, ureido, NO2, etc.; n = 0-4) or a pharmaceutically acceptable salt or an


in vivo hydrolyzable ester thereof were prepared possessing glycogen phosphorylase inhibitory activity (no data). Thus, II was prepared by amidation of 5-carboxy-2,3-dichloro-4H-thieno[3,2-b]pyrrole with 2-phenoxethylamine. As glycogen phosphorylase inhibitors, I have value in the treatment of disease states associated with increased glycogen phosphorylase activity, e.g., type 2 diabetes. Pharmaceutical compns. containing I are described.

IT 403859-70-1P 403859-94-9P 403859-96-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of thienopyrrolyl amides as glycogen phosphorylase inhibitors)
RN 403859-70-1 CAPLUS
CN 4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2,3-dichloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)




RN 403859-94-9 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-(1,2,3,4-tetrahydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 403859-96-1 CAPLUS
CN 6H-Thieno[2,3-b]pyrrole-5-carboxamide, 2-chloro-N-(1,2,3,4-tetrahydro-1-methyl-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT